Research
An experimental treatment improves the cognitive ability and gut microbiota of mice with fragile X syndrome
The Brief
- Ongoing treatment with a drug that inhibits the endocannabinoid system peripherally improved memory deficits in fragile X syndrome mouse models.
- The treatment also reduced synaptic alterations, mitigated gut microbiota dysbiosis and restored intestinal barrier integrity markers.
- The treatment is experimental and the findings come from mice.
Why it matters
The results point to the peripheral endocannabinoid system and the gut as possible targets in fragile X syndrome research, though the evidence so far comes only from mouse models.
Who’s affected
- researchers studying fragile X syndrome
- neuroscientists and gut microbiome researchers
- #fragile x syndrome
- #endocannabinoid system
- #gut microbiota
- #memory
- #mouse models
Ongoing treatment with a drug that inhibits the endocannabinoid system peripherally improves memory deficits, reduces synaptic alterations, mitigates gut microbiota dysbiosis and restores intestinal barrier integrity markers in fragile X syndrome mouse models. This experimental…